Phio Pharmaceuticals Corp.
PHIO
$1.22
-$0.04-3.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 25.06% | 9.96% | |||
| Gross Profit | -25.06% | -9.96% | |||
| SG&A Expenses | -20.17% | 7.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.16% | 8.49% | |||
| Operating Income | -1.16% | -8.49% | |||
| Income Before Tax | 0.88% | -10.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.88% | -10.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.88% | -10.43% | |||
| EBIT | -1.16% | -8.49% | |||
| EBITDA | -1.15% | -8.48% | |||
| EPS Basic | 42.09% | 3.17% | |||
| Normalized Basic EPS | 42.10% | 3.15% | |||
| EPS Diluted | 42.09% | 3.17% | |||
| Normalized Diluted EPS | 42.10% | 3.15% | |||
| Average Basic Shares Outstanding | 71.14% | 14.05% | |||
| Average Diluted Shares Outstanding | 71.14% | 14.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||